BioCentury
ARTICLE | Top Story

Astellas, J&J in autoimmune deal

October 2, 2012 1:29 AM UTC

Astellas Pharma Inc. (Tokyo:4503) granted Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights, excluding Japan, to develop and commercialize autoimmune product ASP015K. The oral JAK inhibitor is ...